Tuyen Ong

841 total citations
23 papers, 196 citations indexed

About

Tuyen Ong is a scholar working on Molecular Biology, Ophthalmology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Tuyen Ong has authored 23 papers receiving a total of 196 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 7 papers in Ophthalmology and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Tuyen Ong's work include Muscle Physiology and Disorders (13 papers), Glaucoma and retinal disorders (4 papers) and Ocular Infections and Treatments (3 papers). Tuyen Ong is often cited by papers focused on Muscle Physiology and Disorders (13 papers), Glaucoma and retinal disorders (4 papers) and Ocular Infections and Treatments (3 papers). Tuyen Ong collaborates with scholars based in United States, United Kingdom and Germany. Tuyen Ong's co-authors include Baldo Scassellati Sforzolini, Robert N. Weinreb, Paul L. Kaufman, Kuldev Singh, Jason L. Vittitow, Mary Richardson, Ezra R. Lowe, Peter Riebling, Xiaohui Luo and Robert J. Spiegel and has published in prestigious journals such as Neurology, American Journal of Ophthalmology and Investigative Ophthalmology & Visual Science.

In The Last Decade

Tuyen Ong

20 papers receiving 188 citations

Peers

Countries citing papers authored by Tuyen Ong

Since Specialization

Citations

This map shows the geographic impact of Tuyen Ong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tuyen Ong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tuyen Ong more than expected).

Fields of papers citing papers by Tuyen Ong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tuyen Ong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tuyen Ong. The network helps show where Tuyen Ong may publish in the future.

Co-authorship network of co-authors of Tuyen Ong

This figure shows the co-authorship network connecting the top 25 collaborators of Tuyen Ong. A scholar is included among the top collaborators of Tuyen Ong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tuyen Ong. Tuyen Ong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Treatment pattern amongst hospitalized HF patients stratified by EF subgroups: Interim review of National Malaysian Heart Failure (MYHF) Registry	International Journal of Cardiology	Azmee Mohd Ghazi, Tuyen Ong et al.	3
2	Meta-analyses of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy	Neuropediatrics	Christian Werner, Xiaohui Luo et al.	0
3	Lung function in ataluren-treated, non-ambulatory patients with nonsense mutation Duchenne muscular dystrophy from a long-term extension trial versus untreated patients from a natural history study	Neuromuscular Disorders	Xiaoting Luo, Joseph McIntosh et al.	1
4	A phase 2 trial of the safety and pharmacokinetics of ataluren in patients aged 2 to 5 years with nonsense mutation Duchenne muscular dystrophy	Neuromuscular Disorders	Peter Riebling, Ronald Kong et al.	1
5	Safety and Tolerability of Ataluren in a Phase 3 Study of Patients with Nonsense Mutation Duchenne Muscular Dystrophy (P3.164)	Neurology	Craig Campbell, Perry B. Shieh et al.	2
6	Ataluren: An Overview of Clinical Trial Results in Nonsense Mutation Duchenne Muscular Dystrophy (P3.162)	Neurology	Craig M. McDonald, K. Bushby et al.	2
7	Use of the Six-Minute Walk Distance (6MWD) Across Duchenne Muscular Dystrophy (DMD) Studies (P3.121)	Neurology	Craig M. McDonald, H. Lee Sweeney et al.	3
8	Results of North Star ambulatory assessments in the phase 3 ataluren confirmatory trial in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD)	Neuromuscular Disorders	Francesco Muntoni, Xiaohui Luo et al.	2
9	Results of North Star Ambulatory Assessments in the Phase 3 Ataluren Confirmatory Trial in Patients with Nonsense Mutation Duchenne Muscular Dystrophy (ACT DMD)	Neuropediatrics	Janbernd Kirschner, K. Bushby et al.	0
10	Results of North Star Ambulatory Assessments (NSAA) in the Phase 3 Ataluren Confirmatory Trial in Patients with Nonsense Mutation Duchenne Muscular Dystrophy (ACT DMD) (I15.008)	Neurology	K. Bushby, Janbernd Kirschner et al.	2
11	ACT DMD: Effect of Ataluren on Timed Function Tests (TFTs) in Nonsense Mutation Duchenne Muscular Dystrophy (P3.163)	Neurology	Nathalie Goemans, Craig Campbell et al.	1
12	Design of a Confirmatory Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study (ACT DMD) of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy	Neuropediatrics	Robert J. Spiegel, A. Reha et al.	1
13	Efficacy of Latanoprostene Bunod Ophthalmic Solution, 0.024%, in Lowering Intraocular Pressure Over 24-Hours in Normal Japanese Subjects (KRONUS)	Investigative Ophthalmology & Visual Science	Makoto Araie, Tuyen Ong et al.	1
14	Besifloxacin Ophthalmic Suspension, 0.6% Compared with Gatifloxacin Ophthalmic Solution, 0.3% for the Treatment of Bacterial Conjunctivitis in Neonatal Patients	Investigative Ophthalmology & Visual Science	Tuyen Ong, Catherine Allaire et al.	1
15	A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study	British Journal of Ophthalmology	Robert N. Weinreb, Tuyen Ong et al.	120
16	Latanoprostene Bunod 0.024% Significantly Reduces and Maintains Mean Diurnal Intra-Ocular Pressure (IOP) Compared to Latanoprost 0.005% in Subjects with Open Angle Glaucoma or Ocular Hypertension	Investigative Ophthalmology & Visual Science	L. Jay Katz, Paul Kaufman et al.	1
17	Prolonged Exposure to Loteprednol Etabonate in Human Tear Fluid and Rabbit Ocular Tissues Following Topical Ocular Administration of Lotemax Gel, 0.5%	Journal of Ocular Pharmacology and Therapeutics	Ezra R. Lowe, Tuyen Ong et al.	11
18	Blinding keratoconjunctivitis and child abuse	American Journal of Ophthalmology	Tuyen Ong, P R Hodgkins et al.	5
19	Latanoprost in port wine stain related paediatric glaucoma	British Journal of Ophthalmology	Tuyen Ong	35
20	Solvent abuse. An anaesthetic management problem	BDJ	Tuyen Ong, I.M. Brook et al.	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact